Cited by 128Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisLung Cancer Diagnosis and TreatmentOccupational and environmental lung diseases

Exacerbation of Idiopathic Interstitial Pneumonias Associated with Lung Cancer Therapy

Open access
Minegishi, Yuji, Takenaka, Kiyoshi, Mizutani, Hideki, Sudoh, Junko, Noro, Rintaro, Okano, Tetsuya, Azuma, Arata, Yoshimura, Akinobu +4 more·2009·Internal Medicine

Abstract

OBJECTIVE AND METHODS: Idiopathic interstitial pneumonias (IIPs) frequently occur in association with lung cancer. However, there is no consensus on the best treatment of acute exacerbation of IIP in lung cancer patients (LC with IIP), including those with iatrogenic acute lung injury resulting from cancer treatments. We aimed to identify an appropriate strategy for treatment of this condition. We analyzed clinical features of 120 LC with IIP, retrospectively. RESULTS: The incidence of acute exacerbation related to anticancer treatment was 22.7%; when the incidence was examined separately for patients receiving chemotherapy or the best supportive care, the incidence was 20.0% and 31.3%, respectively. Additional investigations should be directed to finding suitable regimens for treatment of LC with IIP and the selection of appropriate patients with LC with IIP for chemotherapy. The incidence of acute exacerbation caused by combination regimens of carboplatin + paclitaxel or a platinum agent + etoposide was significantly lower than that of other regimens (0% vs. 18%, respectively; p=0.025, Fisher's Exact Test). Patients with high levels of C-reactive protein before chemotherapy had a significantly higher risk of developing acute exacerbation (odds ratio 5.60, p=0.028). CONCLUSION: There was no evidence that anticancer treatment, including chemotherapy, should be avoided in LC with IIP. To establish an appropriate cancer treatment for LC with IIP, a prospective clinical study should be performed to evaluate various treatment modalities in a larger patient population.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2169/internalmedicine.48.1650

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Drug-induced lung injury occurs more frequently in groups with high CRP, SUVmax, or GPS.

    “Furthermore, drug‑induced lung injury occurs more frequently in groups with high CRP, SUVmax, or GPS(32‑34).”

    From Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy. (2024) · cites this paper as [32]

    The section on risk factors for chemotherapy-induced acute exacerbation of IIPs reports a significantly higher risk when pre-chemotherapy CRP exceeded 2.5 mg/dL in lung cancer patients with IIP. The cited paper does not establish this for SUVmax or GPS, and its finding concerns acute exacerbation in that specific patient group rather than drug-induced lung injury generally. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Minegishi, Y., Takenaka, K., Mizutani, H., Sudoh, J., Noro, R., Okano, T., Azuma, A., Yoshimura, A., Ando, M., Tsuboi, E., Kudoh, S., & Gemma, A.
Affiliations
  • Nippon Medical School (JP)
  • Division of Internal Medicine, Tsuboi Cancer Center Hospital
Venue
Internal Medicine
Published
2009
Volume
48
Issue
9
Pages
665-672
ISSN
  • 0918-2918 (ISSN-L)
  • 1349-7235
OpenAlex
W2094116236
Cited by
128
References
34
Citations by year
2025: 3 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 13 · 2020: 7 · 2019: 15 · 2018: 10 · 2017: 17 · 2016: 4 · 2015: 16 · 2014: 9 · 2013: 3 · 2012: 6
FWCI
4.75
Type
journal article
Language
en
Open access
Locations
  • Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (21591006)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic interstitial pneumonia, lung cancer, acute exacerbation, chemotherapy-induced lung injury, carboplatin, paclitaxel, etoposide, platinum agents, C-reactive protein, best supportive care, treatment selection
MeSH terms
Aged, Aged, 80 and over, Antineoplastic Agents, Female, Humans, Lung Neoplasms, Male, Middle Aged, Retrospective Studies, Survival Rate, Idiopathic Interstitial Pneumonias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review